相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care
Markus Gulilat et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Daniel M. F. Claassens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways
Andrea Huppertz et al.
BMC PHARMACOLOGY & TOXICOLOGY (2019)
Clopidogrel Pharmacogenetics - Why the Wait?
Dan M. Roden
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pharmacogenomics of anticoagulation therapy: the last 10 years
Georgia Ragia et al.
PHARMACOGENOMICS (2019)
Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery
Dmitry Sychev et al.
HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION (2019)
Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants
Sri H. Kanuri et al.
JOURNAL OF PERSONALIZED MEDICINE (2019)
An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure
A. G. Vandell et al.
PHARMACOGENOMICS JOURNAL (2018)
CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis
Dmitriy Alexeyevich Sychev et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2018)
Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives
Adna Asic et al.
PERSONALIZED MEDICINE (2018)
Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis
Qiufen Xie et al.
CURRENT PHARMACEUTICAL DESIGN (2018)
Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study
Anne-Laure Sennesael et al.
THROMBOSIS JOURNAL (2018)
The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty
Dmitriy Alekseevich Sychev et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2018)
Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke
Alexander Valerevich Kryukov et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2018)
Combined Influence of Genetic Polymorphism and DNA Methylation on ABCB1 Expression and Function in Healthy Chinese Males
Lan-Xiang Wu et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2017)
The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban)
Cormac T. O'connor et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin
I. Gouin-Thibault et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation
Satoshi Ueshima et al.
PHARMACOGENETICS AND GENOMICS (2017)
Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism
Laurent Bertoletti et al.
PHARMACOLOGICAL RESEARCH (2017)
Pharmacogentics-based personalized therapy: Levels of evidence and recommendations from French Network of Pharmacogenetics (RNPGx)
Nicolas Picard et al.
THERAPIE (2017)
Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender
Jian Shi et al.
BIOCHEMICAL PHARMACOLOGY (2016)
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability
Claudia Dimatteo et al.
THROMBOSIS RESEARCH (2016)
Pharmacogenetics of dabigatran etexilate interindividual variability
Claudia Dimatteo et al.
THROMBOSIS RESEARCH (2016)
Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect
Kuntheavy Ing Lorenzini et al.
FRONTIERS IN PHARMACOLOGY (2016)
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Christian T. Ruff et al.
LANCET (2015)
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs
Amy L. Kaufman et al.
MAYO CLINIC PROCEEDINGS (2015)
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
Paul A. Reilly et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
Sebastian Harder
THROMBOSIS JOURNAL (2014)
Impact of Endogenous Esterase Activity on In Vitro P-Glycoprotein Profiling of Dabigatran Etexilate in Caco-2 Monolayers
Naoki Ishiguro et al.
DRUG METABOLISM AND DISPOSITION (2014)
Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding
Guillaume Pare et al.
CIRCULATION (2013)
Evaluation of the oral direct factor Xa inhibitor - betrixaban
Michael Palladino et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
The effect of food on the absorption and pharmacokinetics of rivaroxaban
Jan Stampfuss et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
Stephen E. Kimmel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pharmacogenomics Knowledge for Personalized Medicine
M. Whirl-Carrillo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)
Laura M. Hodges et al.
PHARMACOGENETICS AND GENOMICS (2011)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
D. Wang et al.
PHARMACOGENOMICS JOURNAL (2011)
Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant
Michael Ganetsky et al.
JOURNAL OF MEDICAL TOXICOLOGY (2011)
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development
Mike Ufer
THROMBOSIS AND HAEMOSTASIS (2010)
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2008)
ABCB1 genotype and PGP expression, function and therapeutic drug response:: a critical review and recommendations for future research
G. D. Leschziner et al.
PHARMACOGENOMICS JOURNAL (2007)
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
DX Wang et al.
PHARMACOGENETICS AND GENOMICS (2005)
Characterization of the human MDR1 gene
M Bodor et al.
AAPS JOURNAL (2005)
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene
DL Kroetz et al.
PHARMACOGENETICS (2003)
Identification of functionally variant MDR1 alleles among European Americans and African Americans
RB Kim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
dbSNP: the NCBI database of genetic variation
ST Sherry et al.
NUCLEIC ACIDS RESEARCH (2001)
分享论文
